Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, continues its progress in the US market.
Calliditas Therapeutics AB announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon delayed release capsules) versus placebo in patients with primary IgA nephropathy.
Reduce the complexity of device fleet management to deliver seamless mission-critical care.
Device management for mission-critical care: Maximizing efficiency and effectiveness Read More »
Over the next 12 months in healthcare, we expect AI technology will help organizations withstand increasing pressures and improve their confidence.
3 trends that will define the future of healthcare Read More »
Eliminar las malas hierbas de un campo agrícola para evitar que arruinen la cosecha no es tarea fácil. Para proteger los cultivos, los agricultores tienen tres opciones: Rociar el campo agrícola con herbicidas que matan a las malas hierbas pero que pueden contaminar el …
Tres investigaciones cuyos resultados han sido presentados públicamente con poco tiempo de diferencia han explorado hasta qué punto hay relación entre dormir poco y sufrir ciertas dolencias cardiovasculares. El equipo de Soomi Lee, de la Universidad del Sur de Florida e …
Las horas que dormimos y la salud cardiovascular Read More »
Después de pasar 157 días en el espacio, los astronautas de la misión SpaceX Crew-5, a bordo de una nave espacial Dragon, amerizaron sin problemas el 11 de marzo (o 12 dependiendo de la zona horaria) frente a la costa de Tampa, Florida, Estados Unidos, completando la quinta misi …
Los astronautas de la misión SpaceX Crew-5 regresan a la Tierra Read More »
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT Phase III clinical trial with LUMEVOQ®.
Innate Pharma does not have any financial exposure to Silicon Valley Bank Innate Pharma SA has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver.
Innate Pharma Provides Update on Silicon Valley Bank Exposure Read More »
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, informed its shareholders that BioInvent does not hold cash deposits or securities at Silicon Valley Bank, or any other foreign bank.
